Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy

NCT ID: NCT06196632

Last Updated: 2024-02-07

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-01-06
• Study Completion Date: 2025-12-31

Brief Summary

Hepatitis B virus (HBV) infection is prevalent across the world. Functional cure is the optimal endpoint of antiviral therapy for chronic hepatitis B virus (HBV) infection. Currently available anti-HBV therapy includes nucleoside analogs (NAs) and peginterferon-α (Peg-IFNα). Combination of Peg-IFNα and NAs, each with different mechanisms of action, is an attractive approach for treating chronic HBV infection. In this study, we aim to establish logistic regression models to predict durable functional cure in patients with CHB treated by combination of Peg-IFNα and NAs, which might be useful for clinical physicians to make personalized treatment decisions. These models will be constructed using baseline routine clinical laboratory indicators with high diagnostic accuracy. These models might be widely applicable to almost all medical institutions and will effectively promote the application of Peg IFN α plus NAs therapy in clinical work. The findings in this study might greatly improve the functional cure rate of CHB and reducing the incidence rate and mortality of HBV related end-stage liver diseases.

Conditions

Hepatitis B, Chronic

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

"de novo" strategy-HBeAg positive

HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN

Peginterferon-α; Nucleoside analogs

Intervention Type: DRUG

Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

"de novo" strategy-HBeAg negative

HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN

Peginterferon-α; Nucleoside analogs

Intervention Type: DRUG

Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

"add-on" strategy-HBeAg positive

HBeAg positive patients treated with NA followed by addition of Peg-IFN.

Peginterferon-α; Nucleoside analogs

Intervention Type: DRUG

Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

"add-on" strategy-HBeAg negative

HBeAg negative patients treated with NA followed by addition of Peg-IFN.

Peginterferon-α; Nucleoside analogs

Intervention Type: DRUG

Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

Interventions

Peginterferon-α; Nucleoside analogs

Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. Sign an informed consent form;
• 2. HBsAg (+), and the course of the disease exceeds six months;
• 3. Age range from 16 to 70 years old;
• 4. Female participants of childbearing age who had a negative pregnancy test before the trial and were able to take effective contraceptive measures;
• 5. During the treatment period, within six months after the end of treatment, the patients agrees to use contraception

Exclusion Criteria

• 1. Patients with a known history of allergy to Peg-IFNα and NAs;
• 2. Co-infection with other virus such as HAV, HCV, HDV, HEV, HIV, etc;
• 3. Patients with liver cirrhosis or a Child Pugh score of 7 or above;
• 4. History or evidence of liver disease caused by other factors (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced hepatitis, hepatolenticular degeneration, etc.);
• 5. Pregnant or lactating women; Have a history of alcohol or drug abuse within the year prior to the trial enrollment screening;
• 6. Neutrophil count<1.5 × 109/L or hemoglobin<100g/L or platelet count<80 × 109/L; During the trial enrollment screening, serum creatinine was higher than the upper normal limit;
• 7. A history of severe diseases in important organs and tissues such as the heart, brain, kidneys, retina, and muscles;
• 8. Having a history of mental illness or a family history of mental illness, or a Hamilton Depression Scale score greater than 7 points;
• 9. History of endocrine system or autoimmune diseases, such as thyroid disease, diabetes, systemic lupus erythematosus, sarcoidosis, autoimmune thrombocytopenic purpura, etc;
• 10. History of malignant tumors;
• 11. During the trial enrollment screening, suspicious liver malignant tumors were detected by ultrasound, or AFP was greater than 100ng/mL or AFP cannot remain stable within 3 months prior to the experiment;
• 12. Has a history of important organ transplantation;
• 13. Other diseases that researchers believe are not suitable for inclusion.

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qilu Hospital of Shandong University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Qilu hospital of Shandong University

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Shuai Gao, MD;PhD

Role: CONTACT

qilugaoshuai@sdu.edu.cn

+86-18560088213

Facility Contacts

Shuai Gao, MD;PhD

Role: primary

qilugaoshuai@sdu.edu.cn

+86-18560088213

Other Identifiers

KYLL-2023(ZM)-726

Identifier Type: -

Identifier Source: org_study_id